Veracyte (NASDAQ: VCYT) CCO granted new restricted stock units

Rhea-AI Filing Summary

Leite John reported acquisition or exercise transactions in this Form 4 filing.

Veracyte, Inc. reported an equity compensation grant to Chief Commercial Officer-CLIA John Leite. On March 6, 2026, he received two awards of Common Stock totaling 36,181 and 6,578 shares at $0.00 per share as grants rather than open-market purchases or sales. These awards are structured as restricted stock units that vest over time, including a schedule with 25% vesting on March 2, 2027 and quarterly thereafter, and another grant vesting in full on the first anniversary of the grant date, subject to continued employment. Following these transactions, Leite directly owns 150,339 shares of Veracyte common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Leite John

Role Chief Commercial Officer-CLIA

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	36,181	$0.00	--
Grant/Award	Common Stock	6,578	$0.00	--

Holdings After Transaction: Common Stock — 143,761 shares (Direct)

Footnotes (1)

1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leite John

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer-CLIA

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A(1)		36,181	A	$0	143,761	D
Common Stock	03/06/2026		A(2)		6,578	A	$0	150,339	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

2. Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veracyte (VCYT) report for John Leite?

Veracyte reported that Chief Commercial Officer-CLIA John Leite received two equity compensation grants of Common Stock on March 6, 2026, totaling 36,181 and 6,578 shares, issued at $0.00 per share as restricted stock unit awards rather than open‑market trades.

Were the Veracyte (VCYT) insider transactions open-market buys or sells?

The reported transactions were not open-market buys or sells. They were coded as “A” awards, meaning Veracyte granted John Leite shares as equity compensation, with a price per share of $0.00 and vesting conditions instead of cash purchases or sales.

How many Veracyte (VCYT) shares does John Leite hold after these grants?

After the March 6, 2026 equity awards, John Leite directly holds 150,339 shares of Veracyte common stock. This figure reflects his position following the second grant of 6,578 shares and shows his ongoing equity stake tied to the company’s performance.

What are the vesting terms of John Leite’s March 6, 2026 Veracyte (VCYT) awards?

One restricted stock unit award vests 25% on March 2, 2027, with 1/16 vesting each quarter thereafter, subject to continued employment. The other award vests in full on the first anniversary of the March 6, 2026 grant date, also contingent on continued employment.

Does the Veracyte (VCYT) Form 4 indicate any remaining derivative positions for John Leite?

The filing’s derivative summary is empty, indicating no derivative securities such as options or warrants are reported as remaining positions in this particular Form 4. The disclosure focuses solely on non-derivative Common Stock awards granted as restricted stock units.